MA52861B1 - Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple - Google Patents

Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple

Info

Publication number
MA52861B1
MA52861B1 MA52861A MA52861A MA52861B1 MA 52861 B1 MA52861 B1 MA 52861B1 MA 52861 A MA52861 A MA 52861A MA 52861 A MA52861 A MA 52861A MA 52861 B1 MA52861 B1 MA 52861B1
Authority
MA
Morocco
Prior art keywords
methods
sleep apnea
compositions
treatment
simple snoring
Prior art date
Application number
MA52861A
Other languages
English (en)
Other versions
MA52861A (fr
Inventor
Lawrence G. Miller
Barry Wohl
Walter J. Lunsmann
Original Assignee
Apnimed, Inc. (Delaware)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed, Inc. (Delaware) filed Critical Apnimed, Inc. (Delaware)
Publication of MA52861A publication Critical patent/MA52861A/fr
Publication of MA52861B1 publication Critical patent/MA52861B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En général, l'invention concerne des compositions pharmaceutiques comprenant de la (R)-oxybutynine et un inhibiteur de recaptage de la norépinéphrine (NRI) et des méthodes de traitement de l'apnée du sommeil consistant à administrer de la (R)-oxybutynine et d'un inhibiteur de recaptage de la norépinéphrine (NRI). Dans certains modes de réalisation, le NRI est l'atomoxétine.
MA52861A 2018-01-30 2019-01-30 Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple MA52861B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623892P 2018-01-30 2018-01-30
EP19705634.4A EP3746126B1 (fr) 2018-01-30 2019-01-30 Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple
PCT/US2019/015781 WO2019152475A1 (fr) 2018-01-30 2019-01-30 Méthodes et compositions pour le traitement de l'apnée du sommeil

Publications (2)

Publication Number Publication Date
MA52861A MA52861A (fr) 2021-05-05
MA52861B1 true MA52861B1 (fr) 2024-09-30

Family

ID=65441079

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52861A MA52861B1 (fr) 2018-01-30 2019-01-30 Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple

Country Status (27)

Country Link
US (6) US11911351B2 (fr)
EP (2) EP3746126B1 (fr)
JP (3) JP7422666B2 (fr)
KR (2) KR20250156197A (fr)
CN (2) CN118384147A (fr)
AU (2) AU2019214891B2 (fr)
BR (1) BR112020015316A2 (fr)
CA (1) CA3089712A1 (fr)
DK (1) DK3746126T3 (fr)
EA (1) EA202091597A1 (fr)
ES (1) ES2991425T3 (fr)
FI (1) FI3746126T3 (fr)
HR (1) HRP20241412T1 (fr)
HU (1) HUE068505T2 (fr)
IL (1) IL276247A (fr)
LT (1) LT3746126T (fr)
MA (1) MA52861B1 (fr)
MD (1) MD3746126T2 (fr)
MX (2) MX2020008086A (fr)
PL (1) PL3746126T3 (fr)
PT (1) PT3746126T (fr)
RS (1) RS66104B1 (fr)
SG (1) SG11202007226UA (fr)
SI (1) SI3746126T1 (fr)
SM (1) SMT202400400T1 (fr)
UA (1) UA129618C2 (fr)
WO (1) WO2019152475A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202416602A (en) 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
EA202192202A1 (ru) 2019-02-08 2021-11-03 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
CN116391233A (zh) * 2020-09-30 2023-07-04 皇家飞利浦有限公司 用于执行剂量滴定的方法和系统
CA3210092A1 (fr) * 2021-03-04 2022-09-09 Lawrence G. Miller Combinaison de reboxetine et d'un antagoniste du recepteur muscarinique (arm) destinee a etre utilisee dans le traitement de l'apnee du sommeil
KR20230159462A (ko) * 2021-03-24 2023-11-21 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증 치료 방법 및 조성물
EP4334281A1 (fr) 2021-05-04 2024-03-13 Apnimed, Inc. (Delaware) Formes solides de (r)-oxybutynine d-malate
IL309251A (en) * 2021-06-17 2024-02-01 Apnimed Inc Delaware Norepinephrine reuptake inhibitors for the treatment of sleep apnea
CA3259602A1 (fr) 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combinaison d’un antagoniste alpha 2-adrénocepteur de sous-type c (alpha-2 c) et d’un antagoniste du récepteur muscarinique pour le traitement de l’apnée du sommeil
KR20240124995A (ko) 2021-12-22 2024-08-19 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 a2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 노르에피네프린 재흡수 억제제의 조합물
US20250302814A1 (en) * 2022-05-13 2025-10-02 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
KR20250000641A (ko) * 2023-06-27 2025-01-03 주식회사 아스트로젠 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (fr) 1960-07-26
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH11515015A (ja) 1995-10-24 1999-12-21 グルーエネンタール ゲゼルシャフト ミット ベシュレンクテル ハフツング 睡眠無呼吸の抑止方法
CN1660435A (zh) * 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
US20020155113A1 (en) 2001-03-13 2002-10-24 Miyoung Chun Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US20030060513A1 (en) 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
CA2523567A1 (fr) 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Procede destine a favoriser un sommeil ininterrompu par l'administration d'un chlorure de trospium
WO2005063254A2 (fr) 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Analogues de diaryl[a,d]cycloheptene amino substitues utilises comme agonistes muscariniques, et procedes de traitement de troubles neuropsychiatriques
US20060039866A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1827450A4 (fr) 2004-11-17 2009-04-22 Cypress Bioscience Inc Methodes servant a limiter les effets secondaires d'un traitement par mirtazapine
AU2005319367B2 (en) 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
CA2646729A1 (fr) 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methodes et compositions destinees au traitement de l'incontinence urinaire
CA2603920A1 (fr) 2005-04-15 2006-10-26 The Board Of Trustees Of The University Of Illinois Traitement pharmacologique pour le traitement des apnees du sommeil
US20070021921A1 (en) 2005-07-21 2007-01-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Selective resonance of chemical structures
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
HUE032743T2 (en) 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism
WO2008122019A1 (fr) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Amélioration de la tolérabilité de la mirtazapine et de la réboxétine par leur utilisation en combinaison
AR065989A1 (es) 2007-04-09 2009-07-15 Sepracor Inc Metodos y composiciones para el tratamiento de trastornos de la respiracion relacionados con el sueno
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20090048233A1 (en) 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
CN101925349A (zh) 2007-12-21 2010-12-22 欧兰德股份有限公司 替马西泮的口腔崩解片组合物
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
CA2795253A1 (fr) 2010-04-01 2011-10-06 Theravida, Inc. Procedes d'amelioration de la qualite du sommeil
EP2672972B1 (fr) 2011-01-28 2020-11-04 Pfantastic Medical Research Institute, LLC Procédés pour traiter l'apnée obstructive du sommeil
JP2012176958A (ja) * 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
US20160008334A1 (en) 2013-03-05 2016-01-14 Requis Pharmaceuticals Inc. Preparations for the Treatment of Sleep-Related Respiratory Disorders
WO2016062265A1 (fr) 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 Utilisation du monobenzone pour la préparation d'une composition pharmaceutique indiquée pour le traitement du cancer
HRP20192044T1 (hr) 2015-04-27 2020-02-07 Arena Pharmaceuticals, Inc. Agonisti i pripravci 5-ht2c receptora i metode uporabe
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
WO2017031319A1 (fr) 2015-08-18 2017-02-23 Massachusetts Institute Of Technology Traitement par médicament noradrénergique de l'apnée obstructive du sommeil
GEAP202416602A (en) * 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
AU2019216257B2 (en) 2018-01-31 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for limb-girdle muscular dystrophy type 2C
EA202192202A1 (ru) 2019-02-08 2021-11-03 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне

Also Published As

Publication number Publication date
JP2025159230A (ja) 2025-10-17
EP4445951A3 (fr) 2025-01-08
JP7422666B2 (ja) 2024-01-26
EP3746126B1 (fr) 2024-07-31
EA202091597A1 (ru) 2020-10-22
ES2991425T3 (es) 2024-12-03
AU2019214891A1 (en) 2020-08-20
CN111670050A (zh) 2020-09-15
SG11202007226UA (en) 2020-08-28
PT3746126T (pt) 2024-10-21
CA3089712A1 (fr) 2019-08-08
HRP20241412T1 (hr) 2024-12-20
PL3746126T3 (pl) 2024-12-16
AU2019214891B2 (en) 2024-08-01
JP2021516218A (ja) 2021-07-01
UA129618C2 (uk) 2025-06-18
LT3746126T (lt) 2024-10-25
RS66104B1 (sr) 2024-11-29
US11911351B2 (en) 2024-02-27
US20220378724A1 (en) 2022-12-01
US20210038541A1 (en) 2021-02-11
BR112020015316A2 (pt) 2020-12-08
MX2024001713A (es) 2024-02-20
NZ766673A (en) 2025-08-29
KR20200115598A (ko) 2020-10-07
AU2024227631A1 (en) 2024-11-14
MX2020008086A (es) 2021-02-15
HUE068505T2 (hu) 2024-12-28
DK3746126T3 (da) 2024-10-07
KR102874891B1 (ko) 2025-10-21
SMT202400400T1 (it) 2024-11-15
EP3746126A1 (fr) 2020-12-09
FI3746126T3 (fi) 2024-10-10
EP4445951A2 (fr) 2024-10-16
US20260027070A1 (en) 2026-01-29
IL276247A (en) 2020-09-30
US20240156753A1 (en) 2024-05-16
SI3746126T1 (sl) 2025-01-31
WO2019152475A1 (fr) 2019-08-08
KR20250156197A (ko) 2025-10-31
MA52861A (fr) 2021-05-05
US20250186371A1 (en) 2025-06-12
CN118384147A (zh) 2024-07-26
US20240390299A1 (en) 2024-11-28
MD3746126T2 (ro) 2024-12-31
JP2023181322A (ja) 2023-12-21

Similar Documents

Publication Publication Date Title
MA52861B1 (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple
MX2021004431A (es) Procesos novedosos.
MA52219B1 (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
EA201691847A1 (ru) Способы снижения сердечно-сосудистого риска
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
Şahin et al. Duloxetine-induced sleep bruxism in fibromyalgia successfully treated with amitriptyline.
PH12021500006A1 (en) Methods of treatment and prevention of alzheimer's disease
MA63848A1 (fr) Méthodes de traitement d'une splénomégalie
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
EP4279127A3 (fr) Facteur de différentiation de croissance 15 en tant que biomarqueur de metformine
EP3920898A4 (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
UA111480C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ЛІКУВАННЯ СИНДРОМУ ПОДРАЗНЕНОГО КИШЕЧНИКУ, ЯКА ВВОДИТЬСЯ ПЕРОРАЛЬНО, ЩО МІСТИТЬ ТРИМЕБУТИН, СИМЕТИКОН, α-D-ГАЛАКТОЗИДАЗУ, І СПОСІБ ЇЇ ОТРИМАННЯ
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP4069278A4 (fr) Méthodes et compositions pour le traitement et la prévention du diabète de type 1
HUP0401798A2 (hu) Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására
EA202191469A1 (ru) Восстановление посредством антисмысловых олигонуклеотидов abca4 с аберрантным сплайсингом
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
MA27538A1 (fr) Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol
MX2022001159A (es) Nueva formulacion farmaceutica.
MA49754B1 (fr) Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
MY208695A (en) Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
RU2022102195A (ru) Новые способы лечения бокового амиотрофического склероза